

What is claimed is:

1. A composition for forming a compressed solid dosage form comprising a free-flowing compressible admixture of simethicone and an adsorbant, wherein the weight ratio of simethicone to adsorbant is at least about 1:2.22.
2. A composition of claim 1, wherein the weight ratio of simethicone to adsorbant is at least about 1:2.00.
3. A composition of claim 1, wherein the adsorbant comprises a combination of silicified microcrystalline cellulose and magnesium aluminometasilicate.
4. A composition of claim 1, further comprising at least one additional active agent.
5. A composition of claim 4, wherein the active agent is selected from the group consisting of bisacodyl, famotadine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
6. A composition of claim 5, wherein the active agent is loperamide, or pharmaceutically acceptable salts, esters, or isomers thereof.
7. A composition of claim 1 having at least 30 wt% simethicone.
8. A composition of claim 7, having from about 31 wt% to about 35 wt% simethicone.
9. A composition of claim 1 having from about 19 wt% to about 27 wt% silicified microcrystalline cellulose and having from about 31 wt% to about 39 wt% magnesium aluminometasilicate.
10. A composition of claim 9 having from about 23 wt% to about 27 wt% silicified microcrystalline cellulose and from about 33wt% to about 37 wt% magnesium aluminometasilicate.
11. A composition of claim 1, wherein the composition is compressed into a tablet having a hardness value of at least 2 kp/cm<sup>2</sup>.
12. A composition of claim 11, wherein the composition is compressed into a tablet having a hardness value of from about 5 to about 10 kp/cm<sup>2</sup>.

13. A solid oral dosage form comprising a compressed admixture of simethicone, silicified microcrystalline cellulose, and magnesium aluminometasilicate, wherein the simethicone is adsorbed on the silicified microcrystalline cellulose and magnesium aluminometasilicate.
14. A solid oral dosage form of claim 13, wherein the weight ratio of simethicone to adsorbent is at least 1:2.00.
15. A solid oral dosage form of claim 13, wherein the adsorbant comprises silicified microcrystalline cellulose and magnesium aluminometasilicate.
16. A solid oral dosage form of claim 13, further comprising at least one additional active agent.
17. A solid oral dosage form of claim 16, wherein the active agent is selected from the group consisting of bisacodyl, famotadine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof..
18. A solid oral dosage form of claim 17, wherein the active agent is loperamide, or pharmaceutically acceptable salts, esters, or isomers thereof.
19. A solid oral dosage form of claim 13 having at least 30 wt% simethicone.
20. A solid oral dosage form of claim 19, having from about 31 wt% to about 35 wt% simethicone.
21. A solid oral dosage form of claim 13 having from about 19 wt% to about 27 wt% silicified microcrystalline cellulose and having from about 31 wt% to about 39 wt% magnesium aluminometasilicate.
22. A solid oral dosage form of claim 21 having from about 23 wt% to about 27 wt% silicified microcrystalline cellulose and from about 33wt% to about 37 wt% magnesium aluminometasilicate.
23. A solid oral dosage form of claim 13, wherein the composition is compressed into a tablet having a hardness value of at least 2 kp/cm<sup>2</sup>.
24. A solid oral dosage form of claim 13, wherein the composition is compressed into a tablet having a hardness value of from about 5 to about 10 kp/cm<sup>2</sup>.

5

25. A composition for forming a solid dosage form comprising a free-flowing compressible admixture of simethicone, silicified microcrystalline cellulose, magnesium aluminometasilicate.
26. A compressed solid dosage form comprising an admixture of simethicone, silicified microcrystalline cellulose, magnesium aluminometasilicate, wherein the weight ratio of simethicone to adsorbent is at least 1:2.00.
27. A composition of claim 5, wherein the active agent is bisacodyl, or pharmaceutically acceptable salts, esters, or isomers thereof.
28. A composition of claim 4, wherein the active agent is selected from the group consisting of acetaminophen, ibuprofen, naproxen, ketoprofen, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.

10